Extended Data Fig. 5: SND1 binds to Tap1/2 and promotes their degradation. | Nature Cancer

Extended Data Fig. 5: SND1 binds to Tap1/2 and promotes their degradation.

From: Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer

Extended Data Fig. 5: SND1 binds to Tap1/2 and promotes their degradation.The alternative text for this image may have been generated using AI.

a, Endogenous SND1 knockdown in Py8119-OVA cells was confirmed with western blot. b, Tap1/2 mRNA levels in the indicated Py8119-OVA cells that were co-cultured with OT-I splenocytes for 0 or 24 hr was examined by qRT-PCR. n = 3 independent experiments. c, Indicated Py8119-OVA tumor cells co-cultured for 24 hr were treated with 10 μg/ml of actinomycin D for another 8 hr. RNA levels of Tap1/2 in tumor cells were determined by qRT-PCR. n = 3 independent experiments. d-g Py8119-OVA cells with SND1 (d) or MTDH (f) knockdown were subjected to RIP assay after 24 hr co-culture. The interaction between SND1 or MTDH and Tap1/2 was determined by PCR. Tap1/2 RNAs that bind to MTDH (e) or SND1 (g) were quantified and normalized to the pulled down MTDH and SND1 levels, respectively. n = 3 independent experiments. h, Electrophoretic mobility gel shift assay was performed with in vitro transcribed TAP1/2 mRNA incubated with PBS, recombinant MTDH and SND1 alone or in combination. Data represent mean ± SEM. Significance determined by one-way ANOVA analysis with Dunnett’s test for multiple comparisons (b,c,e), or two tailed Student’s t-test (g). Numerical source data for b, c, e, g,and uncropped images for a, d, f, h are provided.

Source data

Back to article page